All In Biotech

Drug Trial Radar · NCT05388669

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 418 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

418

Actual

Start

Aug 5, 2022

Primary completion

Jan 3, 2024

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
May 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.

Conditions

  • Advanced or Metastatic Non-small Cell Lung Cancer

Interventions

  • LazertinibDrug

    Lazertinib tablets will be administered orally.

  • Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)Drug

    Amivantamab injection will be administered subcutaneously by manual injection.

  • Amivantamab IntravenousDrug

    Amivantamab will be administered by IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady StateTime frame: Pre-dose on Cycle 4 Day 1 (each cycle of 28 days)
  2. For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of AmivantamabTime frame: Pre-dose on Cycle 2 Day 1 (each cycle of 28 days)
  3. Area Under the Concentration (AUC) Time Curve of Amivantamab From Day 1 to Day 15 (AUC [Day 1-15]) of Cycle 2Time frame: Cycle 2: Arm A: pre-dose, 24, 48, 72, 96, 168, and 360 hours (hrs) post-dose on Day 1; Arm B: pre-infusion, end of infusion (EOI)+10 minutes, EOI+2, EOI+6, EOI+24, EOI+48, EOI+72, EOI+168, and EOI+360 hrs post dose on Day 1

Locations

187 sites in 20 countries. Site status is shown where the registry gives one.

  • City of Hope Duarte

    Duarte, California

  • City of Hope Orange County Lennar Foundation Cancer Center

    Irvine, California

  • City of Hope Long Beach Elm

    Long Beach, California

  • National Jewish Health

    Denver, Colorado

  • Baptist Lynn Cancer Institute

    Boca Raton, Florida

  • Orlando Health

    Orlando, Florida

  • University of Kansas

    Kansas City, Kansas

  • University of Michigan

    Ann Arbor, Michigan

  • Astera Cancer Care

    East Brunswick, New Jersey

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • NYU Langone Health Laura and Isaac Perlmutter Cancer Center

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Providence Portland Medical Center

    Portland, Oregon

  • Providence Oncology and Hematology Care Clinic Westside

    Portland, Oregon

  • University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • CEMIC (Centro de Educación Médica e Investigaciones Clínicas)

    Buenos Aires, Argentina

  • IADT Instituto Argentino de Diagnostico y Tratamiento

    CABA, Argentina

  • Centro Oncológico Korben

    Chabas, Argentina

  • Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica

    Córdoba, Argentina

  • Sanatorio Allende

    Córdoba, Argentina

  • Clínica Viedma

    Viedma, Argentina

  • Cancer Research SA

    Adelaide, Australia

  • Chris O'Brien Lifehouse

    Camperdown, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Australia

  • St John of God Hospital Murdoch

    Murdoch, Australia

  • Westmead Hospital

    Westmead, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Australia

  • Fundacao Pio XII

    Barretos, Brazil

  • Cetus Oncologia

    Belo Horizonte, Brazil

  • Instituto Cionc de Ensino e Pesquisa S/S

    Curitiba, Brazil

  • Ynova Pesquisa Clinica

    Florianópolis, Brazil

  • Fundacao Sao Francisco Xavier HMC Unidade de Oncologia

    Ipatinga, Brazil

  • UPCO Unidade de Pesquisa Clinica em Oncologia

    Pelotas, Brazil

  • Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS

    Porto Alegre, Brazil

  • Impar Servicos Hospitalares S/A

    Rio de Janeiro, Brazil

  • Oncoclinicas Rio de Janeiro S A

    Rio de Janeiro, Brazil

  • Instituto D Or de Pesquisa e Ensino IDOR

    Rio de Janeiro, Brazil

  • Nucleo de Oncologia da Bahia

    Salvador, Brazil

Showing 40 of 187 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.